SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "L773:1768 3254 OR L773:0223 5234 srt2:(2020-2024)"

Sökning: L773:1768 3254 OR L773:0223 5234 > (2020-2024)

  • Resultat 1-10 av 30
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  •  
2.
  • Benediktsdottir, Andrea, 1990-, et al. (författare)
  • Antibacterial sulfonimidamide-based oligopeptides as type I signal peptidase inhibitors : Synthesis and biological evaluation
  • 2021
  • Ingår i: European Journal of Medicinal Chemistry. - : Elsevier. - 0223-5234 .- 1768-3254. ; 224
  • Tidskriftsartikel (refereegranskat)abstract
    • Oligopeptide boronates with a lipophilic tail are known to inhibit the type I signal peptidase in E. coli, which is a promising drug target for developing novel antibiotics. Antibacterial activity depends on these oligopeptides having a cationic modification to increase their permeation. Unfortunately, this modification is associated with cytotoxicity, motivating the need for novel approaches. The sulfonimidamide functionality has recently gained much interest in drug design and discovery, as a means of introducing chirality and an imine-handle, thus allowing for the incorporation of additional substituents. This in turn can tune the chemical and biological properties, which are here explored. We show that introducing the sulfonimidamide between the lipophilic tail and the peptide in a series of signal peptidase inhibitors resulted in antibacterial activity, while the sulfonamide isostere and previously known non-cationic analogs were inactive. Additionally, we show that replacing the sulfonamide with a sulfonimidamide resulted in decreased cytotoxicity, and similar results were seen by adding a cationic sidechain to the sulfonimidamide motif. This is the first report of incorporation of the sulfonimidamide functional group into bioactive peptides, more specifically into antibacterial oligopeptides, and evaluation of its biological effects.
  •  
3.
  • Bhuma, Naresh, et al. (författare)
  • The effect of side chain variations on quinazoline-pyrimidine G-quadruplex DNA ligands
  • 2023
  • Ingår i: European Journal of Medicinal Chemistry. - : Elsevier. - 0223-5234 .- 1768-3254. ; 248
  • Tidskriftsartikel (refereegranskat)abstract
    • G-quadruplex (G4) DNA structures are involved in central biological processes such as DNA replication and transcription. These DNA structures are enriched in promotor regions of oncogenes and are thus promising as novel gene silencing therapeutic targets that can be used to regulate expression of oncoproteins and in particular those that has proven hard to drug with conventional strategies. G4 DNA structures in general have a well-defined and hydrophobic binding area that also is very flat and featureless and there are ample examples of G4 ligands but their further progression towards drug development is limited. In this study, we use synthetic organic chemistry to equip a drug-like and low molecular weight central fragment with different side chains and evaluate how this affect the compound's selectivity and ability to bind and stabilize G4 DNA. Furthermore, we study the binding interactions of the compounds and connect the experimental observations with the compound's structural conformations and electrostatic potentials to understand the basis for the observed improvements. Finally, we evaluate the top candidates' ability to selectively reduce cancer cell growth in a 3D co-culture model of pancreatic cancer which show that this is a powerful approach to generate highly active and selective low molecular weight G4 ligands with a promising therapeutic window.
  •  
4.
  • Cornacchia, C., et al. (författare)
  • Development of L-Dopa-containing diketopiperazines as blood-brain barrier shuttle
  • 2022
  • Ingår i: European Journal of Medicinal Chemistry. - : Elsevier BV. - 0223-5234 .- 1768-3254. ; 243
  • Tidskriftsartikel (refereegranskat)abstract
    • In our overall goal to develop anti-Parkinson drugs, we designed novel diketopiperazines (DKP1-6) aiming to both reach the blood-brain barrier and counteract the oxidative stress related to Parkinson's Disease (PD). The anti-Parkinson properties of DKP 1–6 were evaluated using neurotoxin-treated PC12 cells, as in vitro model of PD, while their cytotoxicity and genotoxicity potentials were investigated in newborn rat cerebral cortex (RCC) and primary human whole blood (PHWB) cell cultures. The response against free radicals was evaluated by the total antioxidant capacity (TAC) assay. Comet assay was used to detect DNA damage while the content of 8-hydroxyl-2′-deoxyguanosine (8-OH-dG) was determined as a marker of oxidative DNA damage. PAMPA-BBB and Caco-2 assays were employed to evaluate the capability of DKP1-6 to cross the membranes. Stability studies were conducted in simulated gastric and intestinal fluids and human plasma. Results showed that DKP5-6 attenuate the MPP + -induced cell death on a nanomolar scale, but a remarkable effect was observed for DKP6 on Nrf2 activation that leads to the expression of genes involved in oxidative stress response thus increasing glutathione biosynthesis and ROS buffering. DKP5-6 resulted in no toxicity for RCC neurons and PHWB cells exposed to 10–500 nM concentrations during 24 h as determined by MTT and LDH assays and TAC levels were not altered in both cultured cell types. No significant difference in the induction of DNA damage was observed for DKP5-6. Both DKPs resulted stable in simulated gastric fluids (t1/2 > 22h). In simulated intestinal fluids, DKP5 underwent immediate hydrolysis while DKP6 showed a half-life higher than 3 h. In human plasma, DKP6 resulted quite stable. DKP6 displayed both high BBB and Caco-2 permeability confirming that the DKP scaffold represents a useful tool to improve the crossing of drugs through the biological membranes. 
  •  
5.
  •  
6.
  • Gozari, Mohsen, et al. (författare)
  • Chemistry, biosynthesis and biological activity of terpenoids and meroterpenoids in bacteria and fungi isolated from different marine habitats
  • 2021
  • Ingår i: European Journal of Medicinal Chemistry. - ISSY-LES-MOULINEAUX, FRANCE : Elsevier. - 0223-5234 .- 1768-3254. ; 210
  • Forskningsöversikt (refereegranskat)abstract
    • The marine environment with its vast biological diversity encompasses many organisms that produce bioactive natural products. Marine microorganisms are rich sources of compounds from many structural classes with a multitude of biological activities. The biosynthesis of microbial natural products depends on a variety of biotic and abiotic factors in the marine environment, including temperature, nutrients, salinity and interaction with other microorganisms. Terpenoids, as one of the most important groups of natural products in terrestrial microorganisms are important metabolites for marine microorganisms. Here, we have reviewed the chemistry, biosynthesis and pharmacological activities of terpenoids, extracted from marine microbes, and then survey their potential applications in drug development. We also discussed the different habitats in which marine microorganisms are found including sediments, the flora, such as seaweeds, sea grasses, and mangroves as well as the fauna like sponges and corals. Amongst these habitats, marine sediments are the major source for terpenoids producing microorganisms. The marine bacteria produce mostly meroterpenoids, while the fungi are well known for production of isoprenoids. Interestingly, marine-derived microbial terpenoids have some structural characteristics such as halogenation, which are catalyzed by specific enzymes with distinct substrate specificity. These compounds have anticancer, antibacterial, antifungal, antimalarial and anti-inflammatory properties. The information collected here might provide useful clues for developing new medications. (C) 2020 Elsevier Masson SAS. All rights reserved.
  •  
7.
  • Kondratieva, Alexandra, et al. (författare)
  • Fluorinated captopril analogues inhibit metallo-ll-lactamases and facilitate structure determination of NDM-1 binding pose
  • 2024
  • Ingår i: European Journal of Medicinal Chemistry. - : Elsevier. - 0223-5234 .- 1768-3254. ; 266
  • Tidskriftsartikel (refereegranskat)abstract
    • Bacterial resistance to the majority of clinically used ll-lactam antibiotics is a global health threat and, consequently, the driving force for the development of metallo-ll-lactamase (MBL) inhibitors. The rapid evolution of new MBLs calls for new strategies and tools for inhibitor development. In this study, we designed and developed a series of trifluoromethylated captopril analogues as probes for structural studies of enzyme-inhibitor binding. The new compounds showed activity comparable to the non-fluorinated inhibitors against the New Delhi Metallo-ll-lactamase-1 (NDM-1). The most active compound, a derivative of D-captopril, exhibited an IC50 value of 0.3 mu M. Several compounds demonstrated synergistic effects, restoring the effect of meropenem and reducing the minimum inhibitory concentration (MIC) values in NDM-1 (up to 64-fold), VIM-2 (up to 8-fold) and IMP-26 (up to 8-fold) harbouring Escherichia coli. NMR spectroscopy and molecular docking of one representative inhibitor determined the binding pose in NDM-1, demonstrating that fluorinated analogues of inhibitors are a valuable tool for structural studies of MBL-inhibitor complexes.
  •  
8.
  •  
9.
  •  
10.
  • Matić, Josipa, et al. (författare)
  • Sulfone-based human liver pyruvate kinase inhibitors – Design, synthesis and in vitro bioactivity
  • 2024
  • Ingår i: European Journal of Medicinal Chemistry. - : Elsevier BV. - 0223-5234 .- 1768-3254. ; 269
  • Tidskriftsartikel (refereegranskat)abstract
    • Non-alcoholic fatty liver disease (NAFLD) is a prevalent pathological condition characterised by the accumulation of fat in the liver. Almost one-third of the global population is affected by NAFLD, making it a significant health concern. However, despite its prevalence, there is currently no approved drug specifically designed for the treatment of NAFLD. To address this critical gap, researchers have been investigating potential targets for NAFLD drug development. One promising candidate is the liver isoform of pyruvate kinase (PKL). In recent studies, Urolithin C, an allosteric inhibitor of PKL, has emerged as a potential lead compound for therapeutic intervention. Building upon this knowledge, our team has conducted a comprehensive structure-activity relationship of Urolithin C. In this work, we have employed a scaffold-hopping approach, modifying the urolithin structure by replacing the urolithin carbonyl with a sulfone moiety. Our structure-activity relationship analysis has identified the sulfone group as particularly favourable for potent PKL inhibition. Additionally, we have found that the presence of catechol moieties on the two aromatic rings further improves the inhibitory activity. The most promising inhibitor from this new series displayed nanomolar inhibition, boasting an IC50 value of 0.07 μM. This level of potency rivals that of urolithin D and significantly surpasses the effectiveness of urolithin C by an order of magnitude. To better understand the molecular interactions underlying this inhibition, we obtained the crystal structure of one of the inhibitors complexed with PKL. This structural insight served as a valuable reference point, aiding us in the design of inhibitors.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 30
Typ av publikation
tidskriftsartikel (28)
forskningsöversikt (2)
Typ av innehåll
refereegranskat (30)
Författare/redaktör
Mardinoglu, Adil (4)
Grötli, Morten (4)
Winblad, B (2)
Kumar, R. (2)
Uhlén, Mathias (2)
Borén, Jan, 1963 (2)
visa fler...
Soehnlein, O (2)
Karlén, Anders (2)
Kim, Woonghee (2)
Turkez, H. (2)
Andréasson, Måns (2)
Nilsson, Ulf J (2)
Leffler, Hakon (1)
Henriksson, Martin (1)
Håkansson, Maria (1)
Wang, L (1)
El-Seedi, Hesham (1)
Nordlander, Ebbe (1)
Kihlberg, Jan (1)
Walse, Björn (1)
Erdelyi, Mate, 1975 (1)
Hughes, Diarmaid, 19 ... (1)
Larhed, Mats (1)
Rorbach, J (1)
Nilsson, Johan (1)
Edwards, S (1)
Page, BDG (1)
Frankel, A (1)
Bazan, NG (1)
Schnell, R (1)
Gutierrez-de-Teran, ... (1)
Nandakumar, Kutty Se ... (1)
Larsson, Johanna (1)
Sandström, Anja, 197 ... (1)
Danielson, U. Helena ... (1)
Christopoulos, Arthu ... (1)
Carlsson, Jens (1)
Borén, Jan (1)
Blomqvist, Anders, 1 ... (1)
Wieckowska, Anna (1)
Schüler, Herwig (1)
Linusson, Anna, 1970 ... (1)
Zygmunt, Peter M. (1)
Chorell, Erik (1)
Andreasson, Joakim, ... (1)
Bhuma, Naresh (1)
Cao, Sha (1)
Frank, DA (1)
Wannberg, Johan (1)
Jassbi, Amir Reza (1)
visa färre...
Lärosäte
Uppsala universitet (8)
Karolinska Institutet (8)
Kungliga Tekniska Högskolan (5)
Lunds universitet (5)
Göteborgs universitet (3)
Umeå universitet (2)
visa fler...
Högskolan i Halmstad (1)
Stockholms universitet (1)
Linköpings universitet (1)
Chalmers tekniska högskola (1)
visa färre...
Språk
Engelska (30)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (18)
Naturvetenskap (7)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy